John J. Miller, MD

Check out 2 new psychopharmacology innovations!

Psychiatry: one of the most dynamic and rapidly evolving specialties in medicine.

Are you attending Real Psychiatry in January?

The medication treatment of schizophrenia has finally diversified to a novel neurotransmitter system: the muscarinic cholinergic system.

There is still no formal or professional recognition of complex PTSD as a very different disorder than what DSM-5-TR describes for PTSD.

John J. Miller, MD, discusses the risks of untreated PTSD and the importance of implementing more therapeutic tools into treatment paradigms.

Addressing the importance of safe treatments for PTSD, Dr John Miller discusses adverse effect management practices and the role of REMS protocols.

Focusing on the future of PTSD treatment, Dr John Miller outlines how novel treatments can address current challenges and unmet needs in the therapeutic landscape.

John J. Miller, MD, provides an overview of the symptom clusters of PTSD and treatments that are being looked at to improve patient care.

The Psychiatric Times editor-in-chief shares perspectives on how a novel treatment, MDMA-assisted therapy, can potentially change the treatment landscape and improve patients’ lives.

John J. Miller, MD, discusses how the diagnosis and treatment of posttraumatic stress disorder (PTSD) has evolved over time.

Psychiatry is such a young field attempting to improve functioning and quality of life for so many diverse and complex brain disorders that it should be no surprise that our treatment outcomes spread across the spectrum from much improved to progressive decline.

The FDA did not vote to deny approval of MDMA-assisted psychotherapy on June 4, 2024, contrary to all the buzz in the media saying they did. Learn more here.

In this Special Report, get the latest from the American Psychiatric Association Annual Meeting!

The Psychiatric Times Editor-in-Chief discusses the clinical uses and casual prescribing of ketamine for the treatment of psychiatric disorders.

Psychiatric Times Editor-in-Chief shares his thoughts on the FDA Psychopharmacologic Drugs Advisory Committee decision for MDMA.

Understanding the heterogeneity and complexities of the histamine monoamine system.

Pharmacogenomics at the 2024 APA Annual Meeting.

Biases can be apparent in case notes. Psychiatric Times Editor-in-Chief sat down with us at the 2024 APA Annual Meeting to share more.

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 2 of their conversation.

Peter J. Weiden, MD, sat down with Psychiatric Times’ Editor-in-Chief at the 2024 Annual Meeting. Here’s Part 1 of their conversation.

Jonathan M. Meyer, MD, sat down with Psychiatric Times' Editor-in-Chief at the 2024 APA Annual Meeting.

Joseph F. Goldberg, MD, sat down with Psychiatric Times' Editor-in-Chief at the 2024 APA Annual Meeting.

Suicide is a word that conjures a wide range of intense emotions.

STAR*D trial is one of the most important foundational studies in psychiatry to guide the treatment of unipolar major depression. Get ready to explore a dialogue between the original STAR*D authors and a group of authors who call STAR*D into question.

If all violence in the US that is due to mental disorders could be eliminated, 95% to 97% of violent behavior would remain.

Check out this broad range of innovative medications in development with the goal of providing psychiatric clinicians with novel treatments in the quest to decrease patient suffering and improve function and quality of life.

Here's an update on which medications are on the horizon for the treatment of schizophrenia and PTSD.

Since 2006, STAR*D stands out as an icon guiding treatment decisions of major depressive disorder. But what if it is broken?